Administration of beta(2)-adrenergic agonists during the peri-implantation period does not improve implantation or pregnancy rates in intracytoplasmic sperm injection (ICSI) cycles
Nenhuma Miniatura disponível
Data
2003-12-01
Autores
Pinheiro, O. L.
Cavagna, M.
Baruffi, RLR
Mauri, A. L.
Petersen, C.
Franco, J. G.
Título da Revista
ISSN da Revista
Título de Volume
Editor
Kluwer Academic/plenum Publ
Resumo
Purpose: the objective of the present investigation was to determine implantation and pregnancy rates in patients undergoing ICSI and treated with beta(2)-adrenergic agonists, considering the uterine-relaxing action of these agents.Methods: A total of 225 women undergoing ICSI at the Center for Human Reproduction, Sinha Junqueira Maternity Foundation, entered the study. Patient participation in each group was random, by drawing lots, using a randomization table previously elaborated for the study (2:2:1). The group I (90 women) received 10 mg of terbutaline daily for 15 days starting on the day of oocyte retrieval; group II (90 women) received 20 mg of ritodrine daily during the same period of time as group I; group III (45 patients) received no treatment and was used as control. The evaluation was interrupted in 3 patients of group I and in 30 patients of group II because of a high incidence of side effects.Results: Pregnancy, implantation, and miscarriage rates were not significantly different (p>0.05) between the three groups: 29.88%, 13.25%, and 26.9% for group I; 33.33%, 17.5%, and 10.0% for group II; 28.88%, 15.07%, and 15.38% for group III, respectively.Conclusions: the results of this study do not support the routine use of beta(2)-adrenergic agonists during the peri-implantation period in assisted reproductive technology cycles.
Descrição
Palavras-chave
ICSI, implantation rates, ritodrine, terbutaline, uterine contractility
Como citar
Journal of Assisted Reproduction and Genetics. New York: Kluwer Academic/plenum Publ, v. 20, n. 12, p. 513-516, 2003.